Background In sub-Saharan Africa in the 1990s, more than 600 000 people had epidemic meningococcal meningitis, of whom 10% died. The current recommended treatment by WHO is short-course long-acting oily chloramphenicol. Continuation of the production of this drug is uncertain, so simple alternatives need to be found. We assessed whether the efficacy of single-dose treatment of ceftriaxone was non-inferior to that of oily chloramphenicol for epidemic meningococcal meningitis. Interpretation Single-dose ceftriaxone provides an alternative treatment for epidemic meningococcal meningitis-its efficacy, ease of use, and low cost favour its use. National and international health partners should consider ceftriaxone as an alternative first-line treatment to chloramphenicol for epidemic meningococcal meningitis.
Introduction
Epidemics of meningitis due to Neisseria meningitidis serogroup A are reported almost every year from subSaharan African countries, representing more than 600 000 affected individuals in the 1990s alone.
1,2 The case fatality ratio (CFR) is estimated to be 10%, with a further 10-20% of patients developing neurological sequelae. 3, 4 During these epidemics with high numbers of people with meningitis, over-worked health staff often need effective, cheap, and easy-to-use antibiotics to handle the large influx of patients.
Long-acting chloramphenicol (oily suspension) was first proven effective against epidemic meningococcal meningitis in the mid-1970s, 5, 6 and has been recommended by WHO as a regimen of one or two intramuscular injections since 1995· 7 Even though oily chloramphenicol remains active against N meningitidis serogroup A 8 and is critical for the management of meningitis epidemics, continuation of the production of the drug is uncertain, mainly because of the absence of financial market perspectives for this product. 9 Alternative antimicrobial drugs with proven efficacy against N meningitidis include intravenous benzylpenicillin, ampicillin, and intravenous or intramuscular chloramphenicol or ceftriaxone. 10 However, protocols using multiple injections every day are impractical to use in epidemics and only drugs with simple treatment schedules provide an alternative to oily chloramphenicol. Several studies have shown the efficacy of a daily dose of ceftriaxone for 4 days in the treatment of bacterial meningitis. [11] [12] [13] [14] Short-course protocols could also be effective because of the pharmacological properties of ceftriaxone that include a long half-life in blood (8 h ) and in cerebrospinal fluid (CSF; 14 h), as well as residual amounts in CSF above the minimal inhibitory concentration of most of the organisms 24-48 h after injection. 11, [15] [16] [17] [18] Short-course protocols have been tested in two randomised trials. In a study undertaken by Epicentre in 1995, 47 children aged 2-35 months with meningococcal meningitis did not show any substantial difference in clinical failure rates among those receiving a two-injection regimen of ceftriaxone (9%) or oily chloramphenicol (8%). 19 The second small trial compared 2 days of ceftriaxone with 6 days of benzylpenicillin in 36 adults with bacterial meningitis. Recovery rates were 81% and 95%, respectively, with no significant difference shown. 20 We undertook a multicentre, randomised, open-label, non-inferiority trial comparing the efficacy of shortcourse treatment of ceftriaxone with that of oily chloramphenicol in individuals with meningitis recruited during an epidemic in Niger in 2003.
Methods

Patients
The study was undertaken for 1 month (from March 24 to April 27, 2003) during a meningitis epidemic affecting Maradi and Zinder regions in eastern Niger. Our main objective was to compare the clinical effectiveness of one intramuscular injection of ceftriaxone with that of one intramuscular injection of oily chloramphenicol in the treatment of N meningitidis meningitis in an epidemic context. We tested the hypothesis that treatment outcome with ceftriaxone was non-inferior to that of chloramphenicol.
An individual with suspected meningitis was defined as a person admitted to one of eight peripheral health centres or to the Zinder regional hospital with sudden onset of fever or history of fever in the past 24 h associated with at least one of the following symptoms: neck stiffness, impaired consciousness, or petechial rash for patients older than 1 year; or bulging fontanel, axial hypotonia, upwardly turned gaze, or petechial rash for patients younger than 1 year. An individual with confirmed meningitis was defined as having suspected disease with a CSF white-blood-cell count of more than 50 cells per mL and a biological confirmation of N meningitidis meningitis by: pathogen identification in the CSF by gram staining, presence of soluble antigens in the CSF detected by direct agglutination test (Pastorex, Bio-rad Laboratories, CA, USA), pathogen identification in CSF culture, or detection of bacterial DNA of pathogen by PCR. Apart from PCR, laboratory testing was undertaken every day in a study laboratory in Zinder Hospital, Niger. PCR testing was undertaken at the CERMES laboratory in Niamey, Niger.
Individuals with suspected meningitis were included after written informed consent (or oral consent otherwise) was obtained. Patients were excluded if they were younger than 2 months, had a known allergy to one of the two trial drugs, had a recurrent history of meningitis since the beginning of the epidemic, or presented with non-reactive coma or cardiovascular shock. Pregnant and breastfeeding women were also excluded. Standardised data on clinical signs and symptoms were recorded at admission and throughout the follow-up for all patients. The study was approved by the Ministry of Health of Niger and reviewed by an independent ethics committee in France (Comité Consultatif de Protection des Personnes dans Recherche Biomédicale [CCPPRB], St Germain en Laye, France).
Procedures
At inclusion (0 h), medical doctors who were assigned to the study obtained CSF samples by lumbar puncture, undertook a rapid test for malaria diagnosis (Optimal, Diamed, Switzerland), and randomly assigned patients to receive either ceftriaxone (100 mg/kg to a maximum of 4 g, one intramuscular dose) or oily chloramphenicol (100 mg/kg to a maximum of 3 g, one intramuscular dose). Because of field conditions, our trial was not masked-the vials had different appearances and the treating doctors were not masked to which treatment was given. Block randomisation was done with a computer-generated list and the treatment group was allocated with individually sealed envelopes. Principal investigators undertook the randomisation in Paris before the trial began. They did not assign patients to treatment groups in the field. A second single dose (ceftriaxone 75 mg/kg or chloramphenicol 100 mg/kg) was given after 24-48 h in case of clinical failure, which was defined as: state of consciousness remaining severely altered (Glasgow coma score Ͻ11 at 24 h or Ͻ13 at 48 h), no improvement in the state of consciousness since 0 h, appearance or worsened neurological symptoms since 0 h, repeated or persistent convulsions, or axillary temperature above 38·5ºC in the absence of other evident infectious pathological changes. In case of a positive malaria test, artemisinin-based combination therapy was given. Steroids were not used.
Primary outcome was treatment failure, defined by death or clinical failure (as defined above) at 72 h. Rescue treatment for clinical failure at 72 h was intravenous ceftriaxone (100 mg/kg per day) for a minimum of 4 days. Secondary endpoints were: death within 72 h, clinical sequelae at 72 h (judged on gross clinical abnormality), and clinical failure between 24 h and 48 h needing a second injection.
Statistical analysis
The sample size was calculated to show non-inferiority in the proportion of treatment failure at 72 h in the ceftriaxone group compared with the oily chloramphenicol group, which was based on an estimated proportion of treatment failure in the chloramphenicol group of 15% and a difference of less than 10% between the two groups (beyond which non-inferiority could not be proven). We needed a sample size of 175 individuals with confirmed meningococcal meningitis per group to reject the null hypothesis of inferiority of ceftriaxone to oily chloramphenicol, if we considered a one-sided 5% significance level, 80% power, and 10% loss to followup. 21 Primary and secondary endpoints were analysed according to intention-to-treat principles (all individuals with suspected disease included) as well as per-protocol principles (restricted to individuals with confirmed meningococcal meningitis without any additional infection or concomitant antibiotherapy). For each analysis, differences between groups in the distribution of baseline characteristics at admission were tested using the 2 or Fisher's exact test for categorical variables and the Mann-Whitney or t test for continuous variables. We calculated the risk difference and 90% CIs of the primary and secondary outcomes. 21 The difference was regarded as equivalent if the upper limit of its 90% CI was below 10%.
A separate analysis assessing the risk of treatment failure at 72 h with suspected meningococcal meningitis was undertaken for all baseline characteristics using univariate and multivariate logistic regression. Data entry and analyses were undertaken by use of EpiInfo 6.04 (Centers for Disease Control and Prevention, Atlanta, GA, USA) and SPSS 10·0 (SPSS, Chicago, IL, USA) software packages.
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Results
Of the 557 patients screened, 510 were randomly assigned to receive ceftriaxone or chloramphenicol. Of these individuals, 47 (9%) were excluded because they were ineligible and another seven (1%) were lost to follow-up after treatment allocation (figure). At the time of inclusion for the intention-to-treat analysis, 99 (20%) patients had impaired consciousness and 101 (20%) reported a history of severe convulsions ( n/a n/a S pneumoniae 2 (1%) 2 (1%) n/a n/a H influenzae 1 2 (1%) n/a n/a Negative 77 (30%) 56 (23%) n/a n/a No lumbar puncture 7 (3%) 7 (3%) n/a n/a Diagnosis of meningococcal meningitis only 148 (58%) 160 (65%) n/a n/a Data are number (%) unless indicated otherwise. Totals differ because of missing values. n/a=not applicable. Of the 308 patients with confirmed disease analysed per protocol, 160 received ceftriaxone and 148 received chloramphenicol. The distribution of characteristics on admission did not differ significantly between these groups (table 1) . At 72 h, treatment failure was about 5% overall and in each treatment group. 11 (4%) patients died before 72 h and five (2%) of those who survived were classified as clinical failure. CFR was judged equivalent between the two treatment groups (table 2) . The rate of second injection was about 6% in the chloramphenicol group compared with 7% in the ceftriaxone group. Of the patients with reported sequelae, nine (6%) were in the chloramphenicol group and 14 (9%) in the ceftriaxone group. No serious adverse events were reported during the study.
Univariate analysis of all individuals with suspected disease (table 3) showed a strong association between the risk of treatment failure at 72 h and (1) impaired consciousness, (2) either no confirmed disease or meningococcal meningitis associated with another infection, and (3) severe convulsion before admission. We did not record any association between ceftriaxone treatment and risk of treatment failure (odds ratio 1·0, 95% CI 0·6-1·9). However, an association was seen between the risk of treatment failure for children younger than 5 years and that for children older than 14 years, but this relation was not significant (3·0, 0·8-10·3; table 3). In the multiple logistic regression model, only impaired consciousness at 0 h or diagnosis of another disease (alone or associated with meningococcal meningitis) remained significant risk factors for treatment failure at 72 h.
Discussion
Our results suggest non-inferiority of ceftriaxone to chloramphenicol when used as short-course (singledose) treatment against epidemic meningococcal meningitis. 72 h after admission, we showed equivalency in the CFR, clinical failure rate, proportion of second injection, and proportion of sequelae between the treatment groups. Individuals with suspected disease represented more than 90% of those attending health facilities during the study. This exhaustive recruitment and the multiple inclusion sites (eight primary and one secondary health facilities) favour a highly representative sample of the population of individuals with meningitis who consult peripheral health structures during epidemics.
Our study was undertaken in peripheral health structures during the acute phase of an epidemic. Because of on-site constraints, the duration of follow-up was restricted to 72 h after admission, and information about long-term sequelae could not be extrapolated from our data. Patients in clinical failure at 72 h were followed through to complete recovery. Although the risk of relapse after discharge was regarded as low and all patients were advised to return to the clinic in the event of clinical deterioration, no patients returned during the study period. Other studies testing short-course treatment (2-4 days) of ceftriaxone or chloramphenicol with longer follow-up periods than ours also failed to identify individuals with relapsed disease. [11] [12] [13] [14] [22] [23] [24] This scarcity of data could be explained by the fact that CSF is sterile 24-48 h after one injection of ceftriaxone or chloramphenicol. 11, [15] [16] [17] [18] 25 In both of our treatment groups, the CFR was lower than those reported from epidemiological surveillance or prospective studies undertaken during meningitis epidemics. [26] [27] [28] [29] This difference might be due to the exclusion of individuals with the most severe disease and the study conditions that ensured full-time availability of medical staff and material. Previous studies have shown similar CFR and recovery rates without sequelae at 72 h to those in our study. 5, 13, 14, 22, 23 All deaths reported in our study took place within 30 h of admission, and all occurred in patients who presented with impaired consciousness at admission. Furthermore, two-thirds of the patients who died had been diagnosed with another infection, either alone or associated with meningococcal meningitis. Unconfirmed meningococcal meningitis or meningitis associated with another infection was one of the main risk factors for treatment failure at 72 h (table 3) . Our results suggest that during a meningitis epidemic, if fever persists 48 h after a single injection of ceftriaxone or chloramphenicol with a second injection of antibiotics, other diseases such as malaria should be considered and treated immediately.
Antimicrobial drugs recommended during meningitis epidemics in sub-Saharan Africa should also be effective against other pathogens responsible for bacterial meningitis, and affordable for these countries. Resistance of S pneumoniae and H influenzae to chloramphenicol is increasing worldwide, but does not exceed 10% in African countries. [30] [31] [32] [33] By contrast, only a few strains of S pneumoniae that are resistant to ceftriaxone have been isolated in Africa. 34, 35 The cost of generic ceftriaxone has rapidly fallen, since patent rights for this drug expired in most countries. In our study, the average treatment dose was 2 g per person for both drugs. Treatment cost per patient was estimated as US$4-6 for chloramphenicol and $2-3 for ceftriaxone.
In conclusion, ceftriaxone is an equally effective alternative to oily chloramphenicol for the treatment of meningococcal meningitis during epidemics in resourcepoor settings. The good efficacy and ease of use in an epidemic context, effectiveness against pathogens such as S pneumoniae, wide availability, and low cost are good arguments for ceftriaxone use. Future production of oily chloramphenicol is still uncertain. The potential for emergence of resistance of ceftriaxone if inappropriately used is a major concern. Public-health authorities should put mechanisms in place to ensure proper use of ceftriaxone to avoid rapid spread of resistance as seen previously with other broad-spectrum antibiotics.
Recommendations for the conditions of ceftriaxone use, as well as strategies for its introduction and distribution during epidemics, should now be addressed by national and international health partners.
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